TapImmune Inc. Form 10-K Summary
Entity and period: The supplied filing is TapImmune Inc.’s annual report for the fiscal year ended December 31, 2015, filed April 14, 2016. The filing does not identify the registrant as Marker Therapeutics, Inc.; confirm the company and filing match the intended request. The figures below are annual, not standalone fourth-quarter results.
Business context and reporting period
TapImmune described itself as a clinical-stage immuno-oncology company developing peptide and gene-based vaccines. Its principal programs were TPIV 200, a folate receptor alpha vaccine for ovarian and breast cancers, and a HER2/neu vaccine; its PolyStart DNA-expression platform remained preclinical. The company reported no product revenue and no approved products.
Financial performance and position
| Metric | FY 2015 / Dec. 31, 2015 | FY 2014 / Dec. 31, 2014 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense | $4.448 million | $3.182 million |
| Research and development expense | $1.711 million | $0.189 million |
| Operating loss | $6.159 million | $3.371 million |
| Net loss | $34.066 million; $0.78 per share | $30.883 million; $2.00 per share |
| Cash used in operating activities | $4.343 million | $2.187 million |
| Cash and cash equivalents | $6.577 million | $0.142 million |
| Working capital | $(21.360) million | $(1.024) million |
| Accumulated deficit | $133.508 million | $86.310 million |
No meaningful revenue or gross margin was reported. The 2015 net loss included a $27.873 million noncash loss from changes in the fair value of warrant derivative liabilities. At year-end, those liabilities were $26.493 million, compared with $9,000 in 2014; current liabilities totaled $28.006 million. Other reported obligations included $492,000 under a research agreement, $30,000 of promissory notes in default, and a $23,000 related-party note. The filing reports no off-balance-sheet arrangements.
Financing activities provided $10.778 million in cash in 2015, including $9.220 million from warrant exercises; 37.080 million shares were issued upon those exercises. The balance sheet reported 70.551 million common shares outstanding at year-end. The company had 52.106 million warrants outstanding, with exercise prices ranging from $0.10 to $25.00; warrant terms include potential cash payments in certain transactions.
Material changes versus the prior year
- R&D expense rose to $1.711 million from $189,000, and operating expenses increased to $6.159 million from $3.371 million.
- Net loss increased by about $3.183 million, principally reflecting the large 2015 warrant fair-value loss. In 2014, a $26.884 million loss on extinguishment of debt was a major unusual expense.
- Cash increased following equity financings and warrant exercises, but the working-capital deficit widened substantially, largely due to the warrant derivative liability.
- The weighted-average share count increased to 43.947 million from 15.465 million, reflecting significant share issuance and dilution.
Outlook, management commentary, and risks
- Management planned to advance TPIV 200 and the HER2/neu program into Phase II studies in 2016 and continue preclinical development of PolyStart. Management said available cash was expected to fund operations as then structured through the end of 2016, while also stating additional financing was needed and no financing source was committed.
- Phase I reports described positive immune responses in 20 of 21 evaluable TPIV 200 patients and 19 of 20 evaluable HER2/neu patients; the vaccines were described as well tolerated. These are early immune-response findings, not evidence of clinical efficacy.
- Mayo Foundation received a $13.3 million U.S. Department of Defense grant for a planned 280-patient Phase II TPIV 200 trial in triple-negative breast cancer. The filing says the grant covers that trial; it does not establish that all of the company’s development costs are funded.
- TPIV 200 received FDA orphan drug designation for ovarian cancer in December 2015. FDA Fast Track designation for that program was announced February 3, 2016, after the fiscal year-end.
- The independent auditor’s report raised substantial doubt about the company’s ability to continue as a going concern. The company had recurring losses, negative operating cash flow, no revenue, and dependence on additional financing.
- Key risks include clinical and regulatory failure or delay, financing availability and shareholder dilution, warrant-related cash settlement exposure, dependence on Mayo and third-party manufacturers, intellectual-property and licensing risks, and intense competition.
- Management reported ineffective disclosure controls and material weaknesses in internal control over financial reporting, including inadequate segregation of duties, written procedures, period-end reporting controls, and control monitoring. The auditor did not attest to management’s internal-control assessment.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for TapImmune Inc., whereas the request metadata names Marker Therapeutics, Inc.
- Check subsequent filings for actual cash runway, financing raised, clinical-trial starts and enrollment, and spending commitments after December 31, 2015.
- Review warrant terms and current outstanding amounts, including potential cash settlement obligations, registration-related penalties, and dilution from exercise.
- Verify the scope, timing, and funding arrangements for the Mayo/DoD trial and the company’s license fees, milestones, and royalties.
- Resolve filing inconsistencies in the reported TPIV 200 Phase I patient count (22 in one passage and 24 in another) and the stated timing of Mayo license payments.
- Track remediation of the disclosed control weaknesses and any subsequent auditor or restatement disclosures.